Beijing Foyou PharmaLTD Past Earnings Performance
Past criteria checks 3/6
Beijing Foyou PharmaLTD has been growing earnings at an average annual rate of 17.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.3% per year. Beijing Foyou PharmaLTD's return on equity is 14.8%, and it has net margins of 14.9%.
Key information
17.6%
Earnings growth rate
10.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 7.3% |
| Return on equity | 14.8% |
| Net Margin | 14.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Beijing Foyou PharmaLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,424 | 510 | 1,345 | 430 |
| 30 Jun 24 | 3,365 | 529 | 1,282 | 406 |
| 31 Mar 24 | 3,323 | 508 | 1,314 | 364 |
| 31 Dec 23 | 3,340 | 489 | 1,350 | 353 |
| 30 Sep 23 | 3,337 | 488 | 1,428 | 288 |
| 30 Jun 23 | 3,327 | 483 | 1,481 | 270 |
| 31 Mar 23 | 3,312 | 467 | 1,496 | 259 |
| 31 Dec 22 | 3,240 | 439 | 1,494 | 238 |
| 30 Sep 22 | 3,160 | 385 | 1,484 | 228 |
| 30 Jun 22 | 3,059 | 357 | 1,461 | 204 |
| 31 Mar 22 | 2,975 | 340 | 1,446 | 191 |
| 31 Dec 21 | 2,838 | 314 | 1,401 | 177 |
| 31 Dec 20 | 2,535 | 263 | 1,342 | 138 |
| 31 Dec 19 | 2,425 | 219 | 1,398 | 169 |
| 31 Dec 18 | 2,020 | 200 | 1,094 | 140 |
Quality Earnings: 601089 has a high level of non-cash earnings.
Growing Profit Margin: 601089's current net profit margins (14.9%) are higher than last year (14.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 601089's earnings have grown by 17.6% per year over the past 5 years.
Accelerating Growth: 601089's earnings growth over the past year (4.6%) is below its 5-year average (17.6% per year).
Earnings vs Industry: 601089 earnings growth over the past year (4.6%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 601089's Return on Equity (14.8%) is considered low.